National Center for Emerging and Zoonotic Infectious Diseases



Maternal immunization: understanding safety and efficacy and making a strong recommendation

Lakshmi Sukumaran, MD, MPH Medical Officer, Immunization Safety Office

Ashley Brooks, MPH

Health Communication Specialist National Center for Immunization and Respiratory Diseases

ACOG/ACNM Maternal Immunization Webinar March 1, 2018



ACCMEAccreditation

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)™

The American College of Obstetricians and Gynecologists designates this **enduring material** for a maximum of 1 *AMA PRA Category 1 Credit* TMPhysicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this **enduring material** for a maximum of 1 Category 1 College Cognate Credit. The College has a reciprocity agreement with the AMA that allows *AMA PRA Category 1 Credits*TM to be equivalent to College Cognate Credits.

Disclosure of Faculty and Industry Relationships

In accordance with the College policy, all faculty and planning committee members have signed a conflict of interest statement in which they have disclosed any financial interests or other relationships with industry relative to topics they will discuss at this program. At the beginning of the program, faculty members are expected to disclose any such information to participants. Such disclosure allows you to evaluate better the objectivity of the information presented in lectures. Please report on your evaluation form any undisclosed conflict of interest you perceive. Thank you!

This webinar was made possible by cooperative agreement number 6 5 NU38OT000161-05-00 from the Centers for Disease Control and Prevention (CDC) and the Association of State and Territorial Health Officials (ASTHO). Its contents are solely the responsibility of ACOG and do not necessarily represent the official views of CDC or ASTHO.

Our recommended software and hardware configuration is the following:

Windows



Processor: 850MHz or faster processor (or above) Operating System: Windows XP/2000/98 Memory: 512MB of RAM (or above) Screen Resolution: 1024 x 768 (or above) Microsoft Internet Explorer 5.5 (or higher) or Mozilla Firefox 1.5 Adobe Flash Player 8 (or higher) Adobe Acrobat 6 (or higher)

Macintosh



Processor: G3 500MHz or faster processor (or above) Operating System: OS 10.3 (or above) Memory: 512MB of RAM (or above) Screen Resolution: 1024 x 768 (or above) Mozilla Firefox 1.5 or Safari 1.2.2 browser supported for Mac OS X 10.3 or higher Adobe Flash Player 8 (or higher) Adobe Acrobat 6 (or higher)

Conflict of Interest Disclosure: Faculty/Planning Committee/Reviewer/Staff

CONFLICT OF INTEREST DISCLOSURE: FACULTY/PLANNING COMMITTEE/REVIEWER/STAFF

Kevin A. Ault, MD – Research: Inovio and NIH; Consultant: ACI Clinical, Moderna Therapeutics, NIH, CDC, and ACOG; Data and Safety Monitoring Board: NIH, CDC and Novartis

Brenna L. Hughes, MD – Royalties from UpToDate for authorship; Scientific Advisory: Merck

Flor Munoz, MD – Author and Editorial Board: UpToDate; DSMB Member: Moderna, NIH, Propel study, Thrasher; Research (CTA trough Baylor College of Medicine): Biocryst, Alios, Regeneron, Novavax, CDC respiratory and GI viral surveillance, The National Institutes of Health, BMGF - GAIA project - Vaccine safety; Advisory board: WHO - maternal immunization with influenza/GBS projects

Laura E. Riley, MD – Author: UpToDate; Published Author: Wiley Publishing

Geeta K. Swamy, MD – Research: GSK, Novavax, Regeneron; Independent Data Monitoring Committee: GSK; Chairperson, External Data Monitoring Committee: Pfizer

All other faculty, planning committee members, reviewers and staff have no conflict of interest to disclose relative to the content of the presentation.

Course Faculty

Lakshmi Sukumaran, MD, MPH

Medical Officer, Immunization Safety Office Centers for Disease Control and Prevention

Ashley Brooks, MPH

Health Communication Specialist National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention

Learning Objectives

- Discuss the scientific evidence supporting maternal flu vaccination safety and monitoring.
- Educate pregnant patients about the importance of an annual flu vaccine.
- Name three components of a strong recommendation.
- Use CDC ACOG, ACNM and messaging and resources to address patient questions and concerns regarding flu immunization.

Disclaimer

 The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the CDC

BORE > NEWS > HEALTH > HEALTH NEWS

Woman dies of swine flu days after giving birth

A woman who contracted swine flu died just weeks after giving birth to her first child.



56 deaths among US pregnant women Q = trans DAILY®NEWS | NEWS f ₩ ⊠ ⊕ i sources Over 15 Word folko

U.S. swine flu victim before death; delivered baby in coma



in hospital 2 weeks

Family: Former Lincoln woman dies of swine flu during childbirth

A former mayor of Boys Town has died, apparently of swine flu. A paid oblituary in the Lincoln Journal Star says 20-year-old Caitlin Anne Treat Huber died of swine flu a day after giving birt

25 per cent of pregnant women vaccinated even though they are four times more at risk of swine flu



The NEW ENGLAND JOURNAL of MEDICINE



LAURA DOWNLOT	Anorem to have been suffering liver
respondent Commissionalent	unstring with artifica. Prana
	tented all a termined tak of college
UNION were building to be bened	ing up telectric because they prevently
is properly assess and how particle	is equipment to exercise that their local
toda is an alternat is first the spread of	does not report their balls. Experies before that most same of action
for two proop for next relevants, for two proops of the regard to	the second and largers the median of
and second sources and county	the second and have the second of
with county magazing that they in and	fact advant of descentings of cause fact
must in more and the lumber linder	details. In familie, affent it coparise
strend of soul lines.	
general of peopletices. Rescale will be advised to beep believe	care program warmin have been requirie
sean been crowin, while programs	
waters will also be recomply to head	lace results when they do go may
the automouth of their other children, so	Main more a tor part of fedging
they do not forming the ormin feature. The mentioning come annual merceaning	strategy because it is thought to its left
means had proposed meaners and process	converges complements against new
Allow an other for the second second	useful measures, such as regular hand
children an enough to groups must a mid-loss series for	and the second second second second
for fair, promoting a 1000 gaugate fairer fairer	links a patheory, to be published or
	the Automal People Increase automa
and reduiting more true per children.	presidents, and resident in partners
Under him hair hers dere trees men	factors all dot proto and proper
Shift first other patients to be taken to	senses in accommendations that has
Regist in Sector is people have been also in branched as a sector in the sector in the sector is the	have shown up by the head College of Millions and he head College of Case
from brand of Realth Register, & hast	Multime and the heart of the brings of these
and came have been recorded or behaved.	ferror ligarest from both requestation
Officially, there have been on iterate	cast that trials supplicant changes a
A second s	the second design second

ORIGINAL ARTICLE

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

Janice K. Louie, M.D., M.P.H., Meileen Acosta, M.P.H., Denise J. Jamieson, M.D., M.P.H., and Margaret A. Honein, Ph.D., M.P.H., for the California Pandemic (H1N1) Working Group*

38-Day-Old Baby Dies After Persisting Cough

By LARA SALAHI · April 28, 2010



Third baby dies from whooping cough in California

July 23, 2012

Newborn Nearly Dies Contracting Whooping Cough

Whooping Cough Back Again With A Vengeance In California



By MELKATZ / CESINEWS / JAMENA, 2010, 1249 PM

Whooping Cough Epidemic Rages in California: 5 Babies Dead, 910 Infected

Five babies dead from whooping cough so far this year in biggest outbreak for 20 years

CINN Health - Diet + Rtness | Living Well | Parenting + Family

10 infants dead in California whooping cough outbreak From Minter Falce, CNN Outbreak 2010 Disease burden highest in infants during pertussis epidemic

IN MIKABLA CONLEY



OVERVIEW

- Infections and vaccinations during pregnancy
- CDC vaccine safety monitoring in pregnancy
- Results of inactivated influenza vaccine (IIV) and tetanus, diphtheria, and acellular pertussis (Tdap) safety studies in pregnancy
- Maternal vaccine safety recap



Vaccination during pregnancy protects mom and baby


Infections in pregnant women and neonates

- Maternal influenza
 - Physiologic changes during pregnancy \rightarrow severe disease¹
 - 5-fold increased risk of death in pregnant women (typically 2nd/3rd trimester)
- Neonatal influenza
 - No infant vaccine until 6 months of age
 - Infants at high risk of hospitalization and death from influenza²
- Neonatal pertussis
 - Primary immunization series complete at 6 months
 - Majority of pertussis deaths occur in infants < 3 months of age³

- 1. Grohskopf L et al. MMWR (2016).
- 2. Epperson S et al. MMWR (2014).

^{3. 2016} provisional pertussis surveillance report: http://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2014.pdf

Increased susceptibility to severe influenza infection



Potential impacts of exposures during pregnancy

Pre-implantation (0-2 weeks)	Embryonic period (2-9 weeks)	Fetal period (9 weeks - term)	
Injury to a large number of cells → spontaneous abortion	Major defects and altered function of organs	Small for gestational age, intrauterine growth restriction, fetal death, minor malformations, altered function of organs	

Recommendations for influenza vaccine during pregnancy

- Advisory Committee on Immunization Practices (ACIP) recommendations for pregnant women
 - 1960: Pregnant women noted to be at risk of severe illness and were recommended to receive influenza vaccine
 - since 1990s: Vaccination during 2nd and 3rd trimesters recommended
 - 2004: Influenza vaccine recommended for all pregnant women during any trimester of pregnancy
 - 2017: Any licensed, recommended and age-appropriate trivalent, quadrivalent, or recombinant inactivated influenza vaccine can be administered during pregnancy

Recommendations for Tdap vaccine during pregnancy

- ACIP recommendations in pregnant women¹
 - 2006: Tdap booster to post-partum mothers and family members (cocooning)
 - 2011: Tdap for unvaccinated pregnant women after 20 weeks gestation
 - 2012: Tdap for every pregnant woman at every pregnancy regardless of prior immunization status (optimally between 27-36 weeks gestation)

CDC prioritizes maternal vaccine safety

Vaccine licensure process in the United States





Image adapted from: http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf

Why post-licensure vaccine safety monitoring?

- Pregnant women often excluded from pre-licensure clinical trials
- Pre-licensure clinical trails may not detect rare events
- Safety standards for vaccines are high





VAERS: Vaccine Adverse Event Reporting System, VSD: Vaccine Safety Datalink, CISA: Clinical Immunization Safety Assessment




VAERS

Vaccine Adverse Event Reporting System

Co-managed by CDC and FDA







8 participating healthcare organizations



Identifying pregnancies in the VSD

- VSD uses an validated algorithm¹ to identify pregnancy outcomes and start and end dates from electronic health records
- VSD data can be used to link pregnant women to their children
- VSD annual cohort ~3% of US population²
 - ~125,000 pregnancies per year
 - ~90,000 live births per year
- Additional pregnancy data: Height and weight, education, prior pregnancy history, smoking and alcohol use, plurality, delivery type, Apgars, last menstrual period, estimated due date

CISA

Clinical Immunization Safety Assessment

7 participating healthcare organizations

 assist U.S. healthcare providers with complex vaccine safety questions about their patients

conduct clinical research



vaccine safety experts

Influenza vaccine safety studies: mom, baby and pregnancy

Maternal influenza studies – general safety

- IIV and live attenuated influenza vaccines during pregnancy in VAERS, 1990-2009¹
 - No unusual patterns of pregnancy complications or fetal outcomes
- Influenza A (H1N1) 2009 monovalent vaccine during pregnancy in VAERS²
 - No concerning patterns of maternal or fetal outcomes
- IIV during pregnancy in VAERS, 2010-2016³
 - No vaccine safety concerns among pregnant women or their infants

- Moro PL, et al. Am J Obstet Gynecol (2011).
- 2. Moro PL, et al. Am J Obstet Gynecol (2011).
- 3. Moro PL, et al. Drug Saf (2017).

Maternal influenza studies – maternal outcomes

- Medically attended maternal acute events in the VSD^{1,2}
 - Outcomes included allergic reactions, local reactions, neurologic events
 - No increased risk following IIV or monovalent H1N1 vaccines
- Feasibility of text message influenza vaccine safety monitoring during pregnancy^{3,4}
 - Prospective CISA study
 - Post-vaccination fever was infrequent and a typical pattern of maternal and neonatal health outcomes was observed

1. Nordin JD et al. Vaccine (2014)

- 2. Nordin JD et al. Obstet Gynecol (2013)
- 3. Stockwell M et al. AJPM (2017)

^{4.} Registered at ClinicalTrials.gov <u>www.clinicaltrials.gov</u> (NCT01974050)

Maternal influenza studies – pregnancy outcomes

- Spontaneous abortion (SAB) in the VSD^{1,2}
 - No increased risk of SAB in the 28 days following IIV exposure during 2005-2007 influenza seasons¹
 - Increased risk of SAB in the 28 days following IIV exposure during 2010-2012 influenza seasons²
 - Risk seen in women vaccinated in prior influenza season
 - Follow up study evaluating subsequent influenza seasons in progress

Maternal influenza studies – pregnancy outcomes

- Medically attended adverse obstetric events in the VSD^{1,2}
 - Outcomes included hyperemesis, gestational hypertension, gestational diabetes, proteinuria, urinary tract infection
 - No increased risk following IIV or monovalent H1N1 vaccines
- Adverse birth outcomes in the VSD³
 - No increased risk of preterm birth or small for gestational age following IIV

Maternal influenza studies – infant outcomes

- Major birth defects after vaccination in VAERS, 1990 to 2014¹
 - Major birth defects were infrequently reported, with no condition reported disproportionally
- Major structural birth defects in the VSD²
 - No increased risk after first trimester IIV exposure
- Infant mortality and hospitalizations in the VSD³
 - No increased risk of infant death, hospitalization or hospitalizations from respiratory causes following maternal IIV exposure

- 1. Moro PL, et al. Birth Defects Res (2017).
- 2. Kharbanda EO et al. Journal of Pediatrics (2017).
- 3. Sukumaran L et al. Pediatrics [in press]

Systematic reviews and meta-analyses

- Outcomes: fetal death, spontaneous abortion, congenital malformations¹
 - In 19 studies, no increased risk of fetal death, spontaneous abortion, or congenital malformation following influenza vaccine
- Outcomes: stillbirth and spontaneous abortion²
 - In 7 studies, lower risk of stillbirth and no increased risk of spontaneous abortion following influenza vaccine
- Outcome: congenital malformations³
 - In 15 studies, no association was found between congenital defects and influenza vaccination at any trimester or at first trimester
- 1. McMillan M, et al. Vaccine (2015).
- 2. Bratting KN, et al. Clinical Infectious Diseases (2015).

^{3.} Polyzos KA, et al. Obstetrics and Gynecology (2015).

A word about thimerosal

- Currently only used in multi-dose vials of influenza vaccine
- Institute of Medicine: "Immunization safety review: vaccines and autism"1
 - Scientific evidence does not support a causal association between thimerosal-containing vaccines and autism
- CDC study: "Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism"²
 - Case-control study in VSD found prenatal exposure to thimerosal containing immunizations did not increase the risk of autism

Tdap vaccine safety studies: mom, baby and pregnancy

Maternal Tdap studies – general safety

- Adverse events after Tdap vaccines in pregnant women in VAERS, 2005-2010¹
 - During a time when Tdap was not routinely recommended in pregnancy, no concerning patterns in maternal, infant, or fetal outcomes
- Enhanced surveillance of Tdap vaccines in pregnancy in VAERS, 2011-2015²
 - No new or unexpected adverse events were noted among vaccinated pregnant women after routine recommendations for maternal Tdap vaccination
 - Changes in reporting patterns expected, given the broader use of Tdap in pregnant women in the third trimester

- 1. Zheteyeva Y, et al. Am J Obstet Gynecol (2010).
- 2. Moro PL, et al. Vaccine (2016).

Maternal Tdap studies – maternal outcomes

- Medically attended maternal acute adverse events in the VSD¹⁻³
 - Outcomes included local reactions, allergic reactions, neurologic events
 - No increased risk following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines
- Clinical study of Tdap safety in pregnant women in CISA (in progress)^{4,5}
 - Prospective observational study in pregnant and non-pregnant women
 - Preliminary findings: Tdap was well tolerated and immunogenic; proportion of reactions in pregnant women receiving repeat Tdap not higher than those receiving first Tdap
- 1. Kharbanda EO et al. Vaccine (2016)
- 2. Sukumaran L et al. Obstet Gynecol (2015)
- 3. Sukumaran L et al. JAMA (2015)
- 4. Presented to ACIP June 2016
- 5. Registered at ClinicalTrials.gov <u>www.clinicaltrials.gov</u> NCT02209623

Maternal Tdap studies – pregnancy outcomes

- Adverse obstetric events in the VSD¹
 - Small statistically significant increased risk of chorioamnionitis
 - Follow-up study evaluating infant morbidity showed no signals (next slide)
 - No increased risk of hypertensive disorders of pregnancy
- Chorioamnionitis reports to VAERS²
 - Chorioamnionitis was infrequently reported (<1% of pregnancy reports) over a period of 24 years²
- Adverse birth outcomes in the VSD^{1,3,4}
 - No increased risk of preterm delivery, small for gestational age following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines
- 1. Kharbanda EO et al. JAMA (2014)
- Datwani H, et al. Vaccine (2015).
- 3. Sukumaran L et al. Obstet Gynecol (2015)
- 4. Sukumaran L et al. JAMA (2015)

Maternal Tdap studies – infant outcomes

- Birth defects in the VSD¹
 - No increased risk of microcephaly or other structural birth defects
 - Response to concerns of increase in microcephaly in Brazil related to Zika
- Infant morbidity in the VSD²
 - No increased risk of tachypnea of newborn, neonatal sepsis, neonatal pneumonia, respiratory distress syndrome, newborn convulsions after maternal Tdap vaccine despite slight increase in diagnosed chorioamnionitis
- Infant mortality and hospitalizations in the VSD³
 - No increased risk for infant death, hospitalizations or respiratory hospitalizations after maternal Tdap
- 1. DeSilva M et al. JAMA (2016)
- 2. DeSilva M et al. Vaccine (2017)
- 3. Sukumaran L et al. Pediatrics [in press].

Maternal vaccine safety recap

Recap

- Pregnant women and neonates at increased risk of complications from influenza and pertussis disease
 - Vaccination during pregnancy important tool to protect pregnant women and their infants
- Pregnant women often excluded from drug and vaccine pre-licensure trials
 - Post-licensure monitoring crucial
- The CDC has a comprehensive mechanism for monitoring vaccine safety
 - Studies support the use of influenza and Tdap vaccines in pregnancy and are consistent with larger body of evidence

Your recommendation matters

 Consistently shown in literature to be the most influential factor in a patient's decision to receive an immunization



Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases



Maternal Immunization: Understanding Safety and Efficacy and Making a Strong Recommendation

Maternal Vaccination Communication Strategies

Ashley Brooks, MPH Health Communication Specialist National Center for Immunization and Respiratory Diseases

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Overview

- ACIP-recommended immunization schedule for pregnant women
- Research surrounding maternal immunization communication
- Role of health care provider
- Use of CDC, ACOG, and ACNM messaging and resources to address patient questions

ACIP recommendations for pregnant women

Maternal Vaccination

Vaccine	Before pregnancy	During pregnancy	After pregnancy	Type of vaccine
Influenza	Yes	Yes, during flu season	Yes	Inactivated
Tdap	May be recommended; it is better to vaccinate during pregnancy when possible	Yes, during each pregnancy	Yes, immediately postpartum, if Tdap never received in lifetime; it is better to vaccinate during pregnancy	Toxoid/ Inactivated
Td	May be recommended	May be recommended, but Tdap is preferred	May be recommended	Toxoid
Hepatitis A	May be recommended	May be recommended	May be recommended	Inactivated
Hepatitis B	May be recommended	May be recommended	May be recommended	Inactivated
Meningococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
Pneumococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
HPV	May be recommended (through 26 years of age)	No	May be recommended (through 26 years of age)	Inactivated
MMR	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live
Varicella	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live

Influenza and pregnant women

Health and Economic Cost of Influenza

- Millions of cases per year, varies year to year
- 226,000 hospitalizations per year, >75% among adults¹
- 3,000–49,000 deaths per year, >90% among adults²
- Direct medical cost \$10.4 billion³
- With loss of work and life \$87 billion
- Estimates for 2015–2106⁴
 - 25 million illnesses
 - 11 million medical visits
 - 310,000 hospitalizations
 - 12,000 deaths



1. Thompson WW, et al. Influenza-Associated Hospitalizations in the United States. JAMA 2004;292:1333–1340

2. CDC. Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR 2010;59(33):1057–1062

3. Molinari, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007;25:5086–5096

4. CDC. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States, 2017. Available at: www.cdc.gov/flu/about/disease/2015-16.htm


Influenza and Pregnancy

- Influenza illness during pregnancy
 - Higher risk for severe illness and complications
 - Increase in delivery complications (fetal distress, preterm labor, cesarean delivery)
- Vaccinating pregnant women
 - Protective levels of anti-flu antibody for mom, passive transfer of antibody for baby
 - Reduced risk for influenza infection and hospitalizations among infants <6 mos age
 - -36% in respiratory illness for mom, 29% \downarrow for infants <6 mos age
 - 63% \downarrow in lab-confirmed flu among infants <6 mos age
- Influenza vaccination recommended for women who are or will be pregnant
 - CDC, American College of Obstetricians and Gynecologists, American College of Nurse Midwives, American Academy of Family Physicians

• Eick AA et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011;165:104–11


[•] Grohskopf LA et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2013–2014. MMWR 2013;62(RR07);1–43

Influenza Vaccination Coverage Among Pregnant Women, 2010–2011 through 2016–2017 Influenza Seasons



Maternal Flu Vaccine Recommendation

- CDC recommends that pregnant women get a flu shot during any trimester of their pregnancy to protect themselves and their newborn babies from flu.
- By the end of October, if possible, to help ensure protection before flu activity begins to increase



Pertussis and pregnant women

Burden of Pertussis

- Notifiable disease based on clinical, lab, epi criteria
- 21,000 cases in 2015, 22% among adults (underdiagnosed and underreported)
- Transmission from adults to children
 - Disease most severe for infants
 - Among hospitalized, apnea (61%), pneumonia (23%), death (1%)





Pertussis Vaccination Recommendations

Adults

- 1 dose Tdap if previously not received, except for pregnant women

Pregnant women

- Direct protection for mom, indirect protection for baby
- Infants of vaccinated moms were born with significantly higher anti-pertussis antibodies if Tdap given in pregnancy weeks 27–36
- Concentration of anti-pertussis antibodies in infant cord blood higher when mothers vaccinated earlier in this window
- Longer exposure to vaccine allows higher vaccine-induced antibody levels produced by mother and transferred to infant
- Vaccination is recommended for *every* pregnancy
- Cocooning alone may not be effective and it is difficult to implement

Pertussis Vaccination Recommendations

Adults

1 dose Tdap if previously not received, except for pregnant women

Pregnant women

- Direct protection for mom, indirect protection for
- Infants of vaccinated moms were be Tdap given in pregnar
- Administer 1 dose of Tdap every pregnancy preferably during early part of gestational weeks 27-36 miniant cord blood higher when mothers Concent vaccinate
- vaccine allows higher vaccine-induced antibody levels produced by Longer ex mother and transferred to infant

cussis antibodies if



- Pregnant women should get influenza vaccine and Tdap (for every pregnancy)
- But vaccination coverage rates remain low
- We know that health care provider recommendations have big impact
- So, focus on effective messaging and communication strategies

What does communication research tell us?

CDC Maternal Research

Summary of Findings from 2014 Mixed Methods Research

<u>Methodology</u>:

- Surveys
- Focus groups
- In depth interviews

Pregnant Women

- Low disease and vaccine awareness
- Protection for their babies is very important
- Want to be assured of safety
- High information-seeking
- Want information from ob-gyn or midwife

Ob-gyns

- Are recommending vaccines to pregnant patients
- Understand importance of maternal vaccination
- Low perceived susceptibility
- Systems barriers to stocking vaccines

Additional Research: November – December 2016

- Online survey and message testing with pregnant women
 - -251 pregnant women aged 18-45 years in U.S. receiving prenatal care
 - Mixed household income, age, and experience with pregnancy
 - Range of intention for flu and Tdap vaccines

In-depth interviews with HCPs

- -16 OB-GYNs and 8 certified nurse midwives (CNM)
- Across all regions of U.S.
- Included those that provide Tdap onsite + those that refer

Key Findings: Pregnant Women

Vaccine Recommendations

- 69% received flu vaccine recommendation and 41% received Tdap vaccine recommendation
- About 60% who received recommendations (for flu or Tdap vaccine) were told the vaccine was "extremely or very important"

Vaccine Acceptance

- More respondents had gotten or intended to get flu vaccine (59%) than Tdap (42%)
- 28% had decided not to get each of the vaccines
- Vaccine Decision-making
 - Pregnant women get vaccines because their prenatal care providers recommend them or because they heard the illnesses could harm their baby.
- They want information about safety of individual vaccines, side effects, and
 vaccine ingredients.

How HCPs Talk about Maternal Vaccines

- Most use similar Tdap and flu vaccine messages with patients
- Most discuss Tdap and flu vaccination concurrently, during initial intake visit
 - Use printed materials to help educate patients about vaccines
- Key message themes to facilitate vaccine conversations:
 - Disease susceptibility and severity
 - Vaccination benefits (protection, passive immunity)
 - Vaccine safety
- CNMs were more likely than OB-GYNs to feel uncomfortable making a strong recommendation for either vaccine, as they view it as a patient decision

Best Ways to Reach Pregnant Women

- Pregnant women get maternal vaccination formation from 3 main sources:
 - 80% HCPs (most important source for 60%)
 - 50% Internet health resources
 - 33% Family
- However, most are not actively looking for information about pregnancy vaccines
- Some pregnant women would be prompted by messages they see online to ask their HCP about maternal vaccination



Role of Health Care Provider

We know pregnant women have questions once they realize they need vaccines...

dangerous? Is it safe for me and my baby?

Can't I just get it after my baby is born (like my last pregnancy)?

Are these diseases really

Why every pregnancy?

Why hasn't my doctor talked to me about this?

Is it enough to just make sure everyone around my baby is vaccinated (or if we stay away from sick people)?



They may look to many sources for pregnancy-related information





Standards for Adult Immunization Practice


- All health care providers, including those who do not provide vaccine services, have role in ensuring adult patients up-todate on vaccines
- Call to action for adult health care providers to
 - ASSESS vaccination status of all patients at every clinical encounter
 - -Strongly **RECOMMEND** vaccines that patients need
 - -ADMINISTER needed vaccines or REFER to a vaccine service provider
 - **DOCUMENT** vaccines received by patients in state vaccine registries

Present Vaccination as a Standard Part of Obstetric Care

- Provide your patients with information and resources about maternal vaccines during her first prenatal visit, and be sure to mention the timeframe for each vaccine when discussing her pregnancy
- Ensure your staff deliver consistent messaging about the importance of maternal vaccines
- Normalize vaccination as part of your patients' pregnancy care

Making a strong recommendation

Vaccination Uptake by Provider Recommendation and Offer



A Strong Recommendation Makes a Difference

- Providers should talk to pregnant patients about the importance of on-time vaccination
 - Pregnant patients need to be vaccinated to protect them and their babies
 - Pregnant patients may not be aware of the recommendations
 - Healthcare providers are patients most trusted sources of health information during their pregnancies.



Strong Vaccine Recommendation

- CDC's research indicates that some pregnant women do not feel their healthcare providers strongly recommend vaccines
- Providers should state clearly that they would like her to get vaccinated

"Today, I strongly recommend two vaccines to help protect you and your baby against the flu and whooping cough."

HCPs can SHARE information with patients


- SHARE tailored reasons why the recommended vaccine is right for the patient
- HIGHLIGHT positive experiences with vaccines to reinforce the benefits and strengthen confidence in vaccination
- ADDRESS patient questions and any concerns about the vaccines
- REMIND patients about the protection vaccines can help provide from serious diseases
- **EXPLAIN** the potential costs of getting the disease

Resources and Tools

Digital Resources

- Website
- Quiz
- Motion graphic
- Listicle
- Digital Toolkit





www.cdc.gov/vaccines/pregnancy

Print Resources

Making a strong vaccine referral

to pregnant women



Subparticipanty address inclusion on trail cheese having a pole off order, because of the same and types, that we are affected as an effected as the formation of the same of the same size o perpendicular intervention of the second sec Considering and the Constant of Applications and the spin of the Constant of the Constant of the interface of the spin of the Constant of the spin of the Spin

Vacables Reaching Records more a sub-furner's -sur least Map -accri-Thildenine.

the second second here to at any role SCHOOL SHOWS NOT CONT. Is defensive conclusion, ong interest in the sufficient for the end remote confident flow-summer a significant complication.

The set and an advance of the being for the second action of the design of the second Bernerertige farer rate vierer weigenet, weigenet,

Making the Referral	
Using a such a since which consider a such as a sub- trained of the share of the such as a sub- ing solid to a such as the such as a sub-sub- port of the such as a sub-such a sub-sub- port of the such as a sub-sub-sub-sub-sub-sub- trained as a sub-sub-sub-sub-sub-sub-sub-sub-sub-sub-	I
Reads between the second second second second	

vacuas a posterio da "antilitzione na ficier

Maternal Vaccination eres for basilineers probactionals

Vaccines help keep your pregnant patients and their growing families healthy. Last Designed Texastricity (2015)

Vectors	Before	During	Aller	Transf
diare -	1000	to targh ser-		moviese
144	May be represented at		In a contrast contrastor. / the loss maked - Minus Contra Contrast-Index (contrast)	-
	wytermented	daylor name manimi.	-	(test)
figentia .	Wytermainted	Automatic .	dyboard	Included
ingenies.et	Might income that	Aginamati		-
***	Vigite non-second	Republication of Industry from the modeling acts data for specific recommendation	-	-
Participation	Mark according	Residences of a	Aylereenaat	-
10	Apple someoid thrigh Apple (199)		Meta summerse (Node ages a rap.	-
-	Wey to assess that increasing decision		Nylowerski	-
senante	Mayle encoded, Markonst, ave. Chorest for Least	~	Approximation	144

For more information, visits www.ede.gov/vaccinics/programcy Cat an answer to your specific good too by a maring chiming-old gen or calling and CDC INFO (202-Mate)





Callwood .



Next and built same information to work out much activity of the second statements

Puedes empezar a proteger a tu bebé de la tosferina desde antes del nacimiento anternarian para las regiress coloradadas



۰.

Artpany & tasks to

DREAD DOWNARD

d. MOL

Classifie da la constante contribu la factorization. site of the better better better and the data basis moored averaging coverse rules on the model.

Par un idente i normalitari e carine in tada tan Anarda ne artice cari

The second secon distances and other success of resume of holds?

2. Consider a second inter an an a transmission of the

You can start protecting your baby from whooping cough before birth

A Information for progetal in waters

Mitter you get the wheeping chage. pacticle change your 2" intractor, your Lody of the boot will protection anyon wat we horopointy councy's. When do I went to not a refuse your work when here

Why do test to get a first single schedules of the second state of

In this wards a task for the and my bairy?

Yo for an appropriate start of a positive planets have been experienced with the starts, and the second starts about the starts, "in to data search the adjusting via spring produce to COPPERATE AND THAT A DISCONTINUES IN THE

Note and another strong that we say the equations of the set have the properties of the set of the

Weapacout constraints where El constituent las servicies de l'exercice est Senanty roy, Julie to restanty have an interest hard restantion base F

Teaching the second state of the second state Notes an advected to part of a statement with departing the second statement statement of the statement of the source statement statement to a statement of the source statement statement particle for a statement statement statement for an example for gate statement.

Are belies were petting relevaning owigh segments

All belies was set of the AMORPHONE response to the United Materia Yes in a believe some state of a similar parameter of a first set of the Amorphone to the set of the Amorphone resources of the Amorphone to the amorphone set of the sets of the Amorphone set of the Amorphone set of the sets of the Amorphone set of the Amorphone set of the set of the Amorphone set of the Amorphone set of the Amorphone set of the Amorphone set of the Sector set of the Amorphone set of the

managers and short programs.



all lots the an integrated when the

this area to prefer this to prefer the observation

surgers and the balance of the first of the first second to transmission and the second second second

in the third property methods between ease

the same the same or conducting the profiles. man when you will name to be in thy or balls. strats is bare with beleased on galaxies of teachy

www.cdc.gov/vaccines/pregnancy

ACOG Resources



Immunization for Women website

- Patient & Provider Resources:
 - Clinical Guidance
 - FAQs
 - Recommendations
 - Safety
 - Coding and Reimbursement
 - Practice Management



Immunization Information for Ob-Gyns and Their Patients

ACNM Resources

- Talking Points
- Position statements
- FAQ
- Posters, coloring books
- Curriculum
- Other resources
- <u>http://midwife.org/Immunization-Resources-for-Providers</u>

- SuperMom
- <u>http://ourmomentoftruth.co</u> <u>m/your-health/importance-</u> <u>of-vaccines/</u>



What Can YOU Do?

GET VACCINATED

- TALK to pregnant patients about maternal vaccines
 - Tell them way it's important for them and their babies
 - Make the conversation and recommendation memorable and compelling
- ADMINISTER indicated vaccines in your office if possible and FOLLOW UP to ensure receipt
- USE and PROMOTE resources available and encourage others to do the same
 - Include maternal vaccine resources in prenatal information packets
 - Promote resources and products through social media channels
- EDUCATE your staff about maternal vaccines
 - Identify or serve as a Vaccine Champion in your practice
- ENCOURAGE pregnant women to ask questions
- TELL US what else you need to help you communicate about vaccines

www.cdc.gov/vaccines/pregnancy

Contact Information

ACOG

Debra Hawks, MPH dhawks@acog.org

Sarah Carroll, MPH scarroll@acog.org

Sarah Wright, MPH Swright@acog.org

Lindsey Regallis Iregallis@acog.org

Elaine Germano, CNM, DrPH, FACNM eagermano@acnm.org

ACNM

Carol Hayes, CNM, MN, MPH carolhayescnm@gmail.com

Questions?



For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 <u>www.cdc.gov</u>

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.



Extra Slides

Spontaneous abortion (SAB) and influenza vaccine

- Background rates of SAB range from 10-22%
- Miscarriages following (not attributed to) influenza vaccine are expected
- Limited data on first trimester influenza vaccine exposure
 - In a 2015 systematic review, 7 studies evaluating SAB found no risk
- Observational studies have limitations
 - Cannot prove flu vaccine was cause of miscarriage
- Original VSD study evaluating 2005-2007 seasons found no risk
 - Follow up study results expected 2019

How to talk to patients about SAB

- Health care decisions should be an ongoing discussion between provider and patient
- Providers should use clinical judgement, based on factors including the patient's health status, local influenza activity, and then benefits versus potential risks from flu vaccination when deciding whether and/or when to immunize their patient against influenza